For the month of August, Avalere will cover what the new proposed changes to existing bundled payment programs could mean for the healthcare industry. In an exclusive series, experts will discuss what the new bundles include and where to go from here. Kicking off this series is Fred Bentley from our Center for Payment and Delivery Innovation.
Katherine Steinberg comes to Avalere Health with more than 15 years’ experience in the healthcare arena.
Prescription drugs are not outsized contributors to rate increases.
The plans are waiting to see how frameworks will evolve and if physicians embrace them before relying on them to decide which prescription drugs to cover.
Our experts provide a quick glimpse into the role healthcare will play in the 2016 elections and hot topics you can expect to hear about on the campaign trail.
Data show gaps in care integration across provider settings following hospital discharges.
Rates vary widely by state; popular low cost options see smaller increases.
Our expert, Jay Jackson, discusses recent final guidance issued by the FDA on compassionate use.
Wendy Everett, ScD, joins Avalere as a senior advisor.
Recently, Avalere took a look at the gubernatorial elections happening this year, their outlooks, and where they stand on the Exchanges and the Medicaid expansion.
Earlier today, the Centers for Medicare and Medicaid Services (CMS) released participation information for its new Oncology Care Model (OCM) slated to begin July 1.
Recently we examined the various models of specialty pharmacy integration/ownership and how they result in different care coordination dynamics and access to drugs. Our findings demonstrate real value and opportunities in linking medical and pharmacy data to better support the patient journey with services and tools.
Between now and November, Avalere will to bring election content to the public dialogue. Our experts provide a glimpse into the role healthcare will play in the 2016 elections and hot topics you can expect to hear about on the campaign trail.
Shifting to a value-based purchasing (VBP) system provides opportunities to engage payer and provider customers in unique contracting and reimbursement relationships that may optimize market access.
Hepatitis C and Oncology Are Top Therapeutic Area Targets
Avalere Supports the Robert Wood Johnson Foundation in Issuing Two Calls for Proposals
Cost-sharing changes could increase costs for many beneficiaries.
With the recent announcement of the U.S. Food and Drug Administration's (FDA) acceptance of a submission for approval of a second biosimilar to Remicade (infliximab), questions remain for biologics manufacturers, payers, prescribers, and others as to how a mature biosimilars pipeline will begin to evolve in the United States and whether a sustainable competitive specialty market will develop.
On June 1, Josh Seidman participated in a panel discussion hosted by FasterCures to discuss Avalere's collaboration with FasterCures to develop a patient-centric value framework.
Popular low cost options see smaller increases.
